Head-to-head · free
Viking Therapeutics vs Zimmer Biomet Holdings, Inc.
VKTX vs ZBH — return on capital, cash generation, margins and balance sheet side by side.
VKTX
1 / 4
measures where VKTX leads
ZBH
3 / 4
measures where ZBH leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | VKTX · FY2025 | ZBH · FY2025 |
|---|---|---|
| Revenue | $0 | $8.2B |
| Net income | (359.6M) | $705.1M |
| Revenue growth (yearly, multi-year) | — | 1.2% |
| Free cash flow | — | $1.5B |
| Free cash flow margin | — | 17.9% |
| Net cash / (debt) | — | — |
| ROIC | — | 4.8% |
| Return on equity | -47.3% | 5.6% |
| Gross margin | — | 69.7% |
| Operating margin | — | 16.5% |
| Net debt / EBITDA | 0.42x | 3.16x |
Figures are as reported by each company; latest fiscal year shown.
Where Viking Therapeutics's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Zimmer Biomet Holdings, Inc.'s cash went (FY2025)
- Capital spending
- $224.5M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free